cyrilzakka/clinical-trials huggingface dataset:
Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk

The purpose of this study is to investigate the incidence and natural course of inflammatory bowel disease in the southeastern area of Korea.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of inflammatory bowel disease including Crohn's disease and ulcerative colitis
* Followed up for at least 6 months for the correct diagnosis

Exclusion Criteria:

* Patients who do not live in Daegu-Gyeongbuk province
The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients

Coronary allograft vasculopathy represents one of the major limiting factors of long-term survival in heart transplant recipients. While extensively researched, the underlying mechanisms of coronary allograft vasculopathy (CAV) after heart transplantation remain incompletely understood. As CD34+ cells represent one of the key determinants of coronary vascular homeostasis we investigated the potential association between CAV and CD34+ cell count in heart transplant recipients.

In a single-center prospective pilot cohort study, we aim to enroll 55 adult heart transplant recipients. All patients will undergo coronary CT angiography and the presence of CAV will be defined in accordance with the ISHLT criteria. At the time of CT angiography, patient will undergo detailed clinical evaluation, cardiac echo and we will also collect blood samples, perform extensive biochemical analysis and measure CD34+ cell count in peripheral venous blood using Beckman-Coulter Navios EX flow cytometry with standard antibodies according to ISAGE protocol. Biomarkers of angiogenesis will be evaluated using Luminex assay kit.

Eligibility Criteria:
Inclusion Criteria:

* heart transplant recipient
* age \> 18 years
* signed informed consent

Exclusion Criteria:

* multiorgan transplantation
* eGFR \< 30 ml/min
* known hypersensitivity to the contrast media
* history of any malignancy treated with radiation or chemotherapy
* therapy with mTOR inhibitors
* rejection \> 1R within 90 days before enrollment
* G-CSF therapy within 30 days of enrollment
Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

Both pre- and postconditioning seem to protect cardiomyocytes during reperfusion therapy. Investigations both ex vivo and in vivo suggest that a gut derived hormone, Glucagon-Like-Peptide-1 (GLP-1), is able to reduce reperfusioninjury after myocardial ischemia. Results from our own laboratory have shown a marked reduction in infarct size when rat hearts in a Langendorf preparation were exposed to the GLP-1 analogue, exendin-4. The investigators want to investigate to what extent this effect can be translated to humans in the setting of acute STEMI treated with primary PCI when evalutaed by cardiac magnetic resonance imaging.


Eligibility Criteria:
Inclusion Criteria:

* More than 18 years of age.
* STEMI less than 12 hours from onset of pain. STEMI defined as as ST-segment elevation in 2 contiguous electrocardiographic leads of \>0.1 mV in V4 - V6 or limb leads II, III and aVF, or \>0.2 mV in lead V1 - V3.
* TIMI 0-1 in infarct related artery.
* Oral and written informed consent.

Exclusion Criteria:

* Multivessel disease defined by one or more stenoses \>70% in diameter in the non infarct related artery.
* Previous myocardial infarction.
* Stent trombosis.
* Previous CABG.
* Less than TIMI 2 following wiring and predilatation of the infarct related artery but prior to postconditioning or placebo treatment.
* Renal insufficiency (creatinin \>200).
* Pregnancy or lactation.
* Diabetic ketoacidose eller hypoglycemia (plasma glukose \< 2.5 mmol/l).
* Pancreatitis.
Prognosis of Behavioral Addiction in Parkinson's Disease

Our hypothesis is that the conventional treatment of Behavioral Addiction in Parkinson's disease is often not effective, and that affects the motor aspects (worsening akinéto-rigid syndrome and / or worsening of dyskinesia due to higher levodopa doses to compensate for the drop in behavioral addictions) and non-motor (withdrawal syndrome dopamine agonist) anxiously including apathy.

Our goal is to describe the natural history of Behavioral Addiction under the effect of the evolution of the disease and adapt treatment according to the prior art, through a study of a larger population of patients than in the few published studies.


Eligibility Criteria:
Inclusion criteria:

* Age greater than or equal to 30 years
* Parkinson's disease according to the criteria of UKPDSBB
* Time evolution of the top disease or equal to 5 years

Exclusion criteria:

* Lack of Parkinson's disease and atypical parkinsonism
* Patient not previously included in PD-BADGE
Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection

The emergence of asymptomatic patients poses a significant challenge to the prevention and treatment of the epidemic.There have not been any treatment options that reduce the viral load or preventive options that reduce the risk of developing severe conditions.Therefore, present feasibility study of the safety and efficacy of Guduchi Ghan Vati was conducted in asymptomatic patients with COVID-19


Eligibility Criteria:
Inclusion Criteria:

* All hospitalised cases above 18 years of age,
* Diagnosed with Covid-19
* Asymptomatic at the time of admission
* Agree to give consent

Exclusion Criteria:

* Symptoms relating to Covid-19
* Severe vomiting
* Respiratory failure or requiring mechanical ventilation
* Patients having alanine transaminase (ALT) or aspartate transaminase (AST) \> 5 times the upper range of normal limits
* Patients with Covid-19 in critical condition or ARDS or NIAD 8 -point ordinal score-2
* Patients with uncontrolled diabetes mellitus
* Malignant,
* Chronic renal failure or
* On immunosuppressive medication
Basal Cell Carcinoma Recurrence After Mohs Surgery

Basal cell carcinoma (BCC) is the most common skin cancer in the US and can cause significant adverse effects.

Mohs micrographic surgery, the treatment of choice for higher risk BCC, allows for removal of lesions with preservation of healthy tissue. Although the BCC recurrence rate post Mohs surgery is estimated at 1-2%, recent data is lacking to validate this historical measurement.

Our purpose is to determine the current recurrence rate of BCC after Mohs surgery.

Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in the United States, affecting nearly one million of all Americans. While BCC is rarely mortal, it has significant associated physical, psychological, and monetary costs to patients such as disfigurement and sensory loss. Individuals who have been diagnosed with at least one BCC lesion are likely to be diagnosed with more in the future. Treatment of these lesions and recurrent physician appointments can be a great inconvenience to patients, resulting in expenses to patients and loss of work and family time.

The Mohs surgery technique is associated with a low recurrence rate for BCC and is preferred for higher risk tumors and for tumors in cosmetically sensitive sites on the head and neck. While recurrence rates of BCC post Mohs are 1-2% for primary basal cells, recent data is not available to validate this historical assessment. Currently, comprehensive rates of recurrence are not available because a national registry of recurrence rates for BCC and squamous cell carcinoma (SCC) does not exist.

The purpose of this study is to both historically and prospectively assess current basal cell carcinoma recurrence rates in patients undergoing Mohs micrographic surgery.

Eligibility Criteria:
Inclusion Criteria:

* Subjects with BCC lesions on the head, neck, genitalia, hands, or feet
* Subjects who have undergone Mohs micrographic surgery for BCC on or before December 31, 2006
* Subjects with a medical record at the respective site
* Subjects in a stable health condition, as determined by the principle investigator

Exclusion Criteria:

* Subjects with basal cell nevus syndrome
* Subjects with lesions only in areas other than the head, neck, genitalia,
* hands and feet
* Subjects who have not followed up through the Department of Dermatology
* Subjects with recurrent BCC lesions diagnosed on or prior to the recorded date of Mohs surgery
Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes

Diabetes and Periodontitis are both prevalent diseases affecting millions of Americans. Periodontitis is prevalent among Diabetics. Furthermore, Periodontitis and associated inflammation can increase insulin resistance in Diabetics and worsens the condition. Hyperbaric Oxygen Therapy (HBOT) has the potential to improve periodontal treatment outcome in poorly controlled diabetics. The study will compare periodontal treatment (SRP) outcome between 2 main diabetic type 2 patient groups receiving medical care treatment: either Conventional Wound Therapies (CWC) with or without adjunctive Hyperbaric Oxygen Therapy at LLU Health.

24 poorly controlled diabetic mellitus (DM) type 2 subjects (HbA1c =\>7%) with Periodontitis will be assigned into the study arms HBO therapy and Non HBO therapy, based on their medical needs.

For all subjects demographic data (age, gender, ethnicity, smoking history, alcohol use history, BMI, current medication list) and oral health habits will be obtained. Blood samples for HbA1c determinations, clinical periodontal measurements (plaque index, probing measurements including pocket depth, attachment levels, gingival index and bleeding-on-probing) and subgingival microbial samples will be obtained at baseline and end of the study. Subgingival microbial samples will be collected from three randomly selected sites and analyzed for detection of about 300 of the most prevalent oral bacterial species. Differences in periodontal clinical outcomes and bacterial profiles will be identified utilizing ANCOVA (Analysis of Covariance).


Eligibility Criteria:
Inclusion Criteria:

* Diabetes type 2 (HbA1c =\>7%)
* Generalized moderate to severe chronic periodontitis.
* Minimum of 10 permanent teeth
* Registered LLU patients

Exclusion Criteria:

* Well controlled Diabetes type 2
* Other systematic conditions with known associations to periodontitis
* Intra-oral conditions which may interfere with the accuracy of periodontal probing
* BMI greater than 45%
Development of Preclinical Models Derived from Tumors with a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.

This study aims to collect tumor samples from patients carrying a mutation of interest to develop a cell culture technique for "spheroids.

The goal is to use these spheroids to model responses to anticancer treatments. Various therapeutic molecules can be tested on these spheroids, enabling the evaluation of the potential of new molecules or the activity of existing ones specifically on the tumor (bearing the mutation of interest) from which the spheroid was developed.

Tumor samples will be collected as part of biopsies or surgeries conducted during routine patient care.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 years or older.
* Patient for whom at least one mutation deemed of interest by the investigator has been identified.
* Patient with a malignant tumor at a locally advanced or metastatic stage, for whom a tissue tumor sample (via surgery, radiology, or endoscopy) is scheduled as part of their standard care.
* Tumor volume deemed sufficient by the physician to ensure an adequate amount of material for analysis by the pathologist and the transfer of a part of the tumor sample to the Laboratory of Translational Research in Oncology for the study.
* INR \< 1.5; Platelets \< 50,000/μL.
* Patient who has been informed of the study and has signed the informed consent form.
* Patient affiliated with a social security insurance.

Exclusion Criteria:

* Patient with multiple primary malignant tumors.
* Patient with a known HIV, Hepatitis C, or Hepatitis B infection.
* Patient on:

  * Clopidogrel (hydrogensulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) with no possibility of suspension for 5 days,
  * Low molecular weight heparin with no possibility of dose suspension before the procedure,
  * Fondaparinux with no possibility of suspension,
  * Abciximab with no possibility of suspension for 24 hours and aPTT \< 50s and ACT \< 150s,
  * Eptifibatide or Tirofiban Hydrochloride Monohydrate or Argatroban with no possibility of suspension 4 hours before the procedure,
  * Bivalirudin with no possibility of suspension 2-3 hours if CrCL \>50 mL/min or 3-5 hours if CrCL \<50 mL/min before the procedure,
  * Dabigatran etexilate with no possibility of suspension 2-3 days if CrCL \>50 mL/min or 3-5 days if CrCL \<50 mL/min before the procedure.
* Patient considered vulnerable; vulnerable persons are defined in articles L1121-5 to L1121-8:

  * Pregnant women, parturients, and breastfeeding mothers,
  * Individuals deprived of their liberty by a judicial or administrative decision, individuals hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and individuals admitted to a healthcare or social facility for reasons other than research,
  * Adults under legal protection or unable to express their consent.
Mindfulness-Oriented Recovery Enhancement For Chronic Pain and Prescription Opioid Misuse in Primary Care

The central aim of this study is to test the efficacy of Mindfulness-Oriented Recovery Enhancement (MORE), an intervention designed to disrupt the risk chain leading from chronic pain to prescription opioid misuse and addiction. The investigators plan to conduct a full scale clinical trial to determine whether MORE (relative to a support group control condition) can reduce symptoms of chronic pain and opioid misuse among patients who are receiving pain management in primary care via long-term opioid analgesic therapy.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-60+
* Current back pain diagnosis as determined from ICD-9 codes in claims data (including but not limited to ICD-9 diagnoses 724.x, or 847.x) or current chronic pain diagnosis determined by physician assessment (including but not limited to ICD-9 diagnoses 338.0, 338.21, 338.22, 338.28, 338.29, 338.4)
* Current use of prescription opioid agonist or mixed agonist-antagonist analgesics for \>90 days, and evidence of opioid misuse as indicated by the Current Opioid Misuse Measure
* Willingness to participate in study interventions and assessments

Exclusion Criteria:

* Prior experience with Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, or Mindfulness-Based Relapse Prevention
* Active suicidality, schizophrenia, psychotic disorder, and/or substance dependence (other than opioid dependence)
* Presence of clinically unstable systemic illness judged to interfere with treatment
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or improving vision when compared to Macugen alone. Patients must be recently diagnosed with predominantly classic wet AMD and must be eligible for PDT.


Eligibility Criteria:
Inclusion Criteria:

* Subjects of either gender; aged 50 years or greater.
* Subfoveal choroidal neovascularization (CNV) due to AMD with predominantly classic lesion composition
* Best corrected visual acuity in the study eye between 20/40 and 20/200

Exclusion Criteria:

* Any prior PDT with Visudyne to the study eye
* Any previous AMD thermal laser therapy to the study eye
High Definition Single Cell Analysis in Colorectal Cancer

This research clinical trial studies high definition single cell analysis in blood and tissue samples from patients with colorectal cancer which has spread to the liver. High definition single cell analysis allows doctors to study the properties of cancer cells that are sometimes found in the blood of patients and to determine how the genes and proteins in them may change over time. Studying samples from patients with colorectal cancer in the laboratory may help doctors learn more about how cancer spreads, as well as how to predict the disease outcomes in patients with cancer.

PRIMARY OBJECTIVES:

I. To determine the level of correlation between solid tumor touch preparations and liquid biopsies (circulating tumor cells \[CTCs\]) from patients with surgically resected colorectal cancer (CRC) metastases to the liver using single-cell high-content analysis, including gene copy number variation (CNV) and to establish one or more bio-signatures that represent the liquid and solid biopsy correlation for each patient and for the patient population.

SECONDARY OBJECTIVES:

I. To demonstrate the technical validity and reproducibility of the bio-signatures by comparing the two pre-resection liquid biopsy samples drawn one week prior to and on the day of surgery.

TERTIARY OBJECTIVES:

I. Compare biosignatures between pre-surgical and post-surgical blood samples. II. Compare biosignatures between resected metastatic liver tumor tissue, primary colon tumor tissue (if available), and pre-surgical blood samples.

III. Compare biosignatures between blood samples prior to resection with those obtained after resection and at the time of recurrence.

OUTLINE:

Patients undergo blood collection 1 week prior surgery, before and after surgery on the same day, and 1 week and 3 months after surgery. Patients also undergo tissue collection during the surgery. Blood and tissue samples are processed for high definition single cell analysis including whole-genome CNV profiles, protein expression, and cell morphology.

After completion of study, patients are followed up for up to 2 years.

Eligibility Criteria:
Inclusion Criteria:

* Able to provide informed consent
* Metastatic colorectal adenocarcinoma to the liver (hepatic mCRC)

  * Synchronous or metachronous
  * Solitary or multifocal
  * Concurrent abdominal lymph node metastasis is allowable
* Hepatic mCRC deemed surgically resectable by the study team with plans to undergo surgery
* Has not received any systemic chemotherapy for at least 21 days prior to scheduled hepatic resection

Exclusion Criteria:

* Non-adenocarcinoma metastatic colorectal cancer (e.g. neuroendocrine carcinoma); mucinous component is permitted
* Metastatic CRC that involves organ(s)/tissue(s) other than abdominal lymph nodes and/or liver
* Has received any systemic chemotherapy within 21 days prior to scheduled hepatic resection
The Diagnostic Value of Autoimmune Antibody Detection in Newly Onset and Chronic Epilepsy

multi-central and prospectively study the diagnostic value of autoimmune antibody detection in new and chronic epilepsy, and provide reference for clinical practice

multi-centrally recruit patients with newly onset or chronic epilepsy and hoping to find whether there exist an autoimmune cause. whether the patients receive immune therapy or not will depend on the type and titter of the autoimmune antibody as well as the severity of the symptom. At 3 and 6 months later, all patients will be followed-up, and the positive autoimmune antibody will be redetected. the clinical manifest, clinical data, medication and treatment outcome will be recorded and analyzed, to study the diagnostic value of autoimmune antibody detection in new and chronic epilepsy

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with epilepsy according to the diagnostic criteria of International League Against Epilepsy (ILAE) 2017
* Age from 16 to 70 years old
* The etiology of patients with epilepsy is unknown
* The patient or guardian signs an informed consent and can cooperate with the inspection and follow-up for six months

Exclusion Criteria:

* Patients with hereditary, infectious, and metabolic epilepsy
* The investigation and follow-up cannot be completed due to vision, hearing, language expression, disturbance of consciousness, and impaired understanding, and the guardian cannot replace the completed
* Patients with other progressive or systemic diseases
A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder

The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder


Eligibility Criteria:
Inclusion Criteria:

* Patients with Generalized Social Anxiety Disorder as the primary diagnosis.
* If female, must commit to consistent and correct use of an acceptable method of birth control.

Exclusion Criteria:

* Patients with any other psychiatric disorder as a primary diagnosis or within 6 months prior to screening.
* Patients with Body Dysmophic Disorder, Schizophrenia, Schizoaffective Disorder, or a Bipolar Disorder.
* Patients who pose a current suicidal or homicidal risk or have made a suicide attempt within the past 6 months or have ever been homicidal.
* Patients who have a positive urine test at screen for illegal drug use and/or a history of substance abuse or dependence (alcohol or drugs) within the past 12 months.
* Patients with an unstable medical disorder.
* Female patients who are pregnant, lactating, or planning to become pregnant during a specified time during the study.
* Patients who are taking other psychoactive medications.
Kinesiophobia in Familial Mediterranean Fever

Kinesiophobia is a common problem in patients with rheumatic disease and can cause physical inactivity, social isolation, disability, and poor quality of life. This study aimed to evaluate kinesiophobia and associated factors in patients with familial Mediterranean fever (FMF). All patients were evaluated in terms of sociodemographic characteristics and assessed using the Tampa Kinesiophobia Scale (TKS), International Physical Activity Questionnaire (IPAQ), Fatigue Severity Scale (FSS), and Hospital Anxiety and Depression Scale (HADS).

Familial Mediterranean fever (FMF) is a common autoinflammatory disease among certain ethnic groups living in the Mediterranean basin. The reported prevalence of FMF among children in Turkey is 9.3/10000. Kinesiophobia is a common problem in patients with rheumatic disease and can cause physical inactivity, social isolation, disability, and poor quality of life. This study aimed to evaluate kinesiophobia and associated factors in patients with familial Mediterranean fever (FMF). All patients were evaluated in terms of sociodemographic characteristics and assessed using the Tampa Kinesiophobia Scale (TKS), International Physical Activity Questionnaire (IPAQ), Fatigue Severity Scale (FSS), and Hospital Anxiety and Depression Scale (HADS).

Eligibility Criteria:
Inclusion Criteria:

* being age over 18
* being volunteer

Exclusion Criteria:

* ortopedic, neurologic, cardiopulmonary diseases that prevent physical activity
* psychological diagnosis and drug usage
Cholecalciferol on Hemodialysis Patients

* Screening the prevalence of vitamin D deficiency among Egyptian hemodialysis patients on a single center (Ain Shams University hospital).
* Assessing the effect of the native type of vitamin D (Cholecalciferol) on replenishing its deficiency via extra-renal vitamin D receptors (VDR), among Egyptian hemodialysis patients.
* Assessing the effect of cholecalciferol on vascular calcification among Egyptian hemodialysis patients.
* Assessing the effect of cholecalciferol on Blood pressure, parathyroid hormone.


Eligibility Criteria:
Inclusion Criteria:

1. Both sexes aged between 18-75 years
2. Patients on HD greater than 3 months at least.
3. Stable clinical condition (no hospitalization in the previous 3 months)
4. Informed consent in accordance with the Declaration of Helsinki.
5. PTH level between 150 - 800 pg/ml.

Exclusion Criteria:

1. Hypersensitivity to cholecalciferol.
2. Participant in an another clinical trial within the past 4 weeks.
3. Judged to be unsuitable as a subject by the attending physician.
4. Pregnant or breastfeeding female